title: Differential modulation of interleukin 8 by interleukin 4 and interleukin 10 in HepG2 cells treated with acetaldehyde.
abstract: OBJECTIVE
  Pro-inflammatory cytokines and chemokines, such as interleukin (IL) 8, are important mediators of hepatic injury and repair following an insult. The purpose of this work was to study the regulation of IL-8 by IL-10 and IL-4 in HepG2 cells treated with acetaldehyde (Ac).
  
  
  METHODS
  HepG2 cells were pretreated with IL-10 or IL-4 before exposure to Ac, examining IL-8 expression by reverse transcription polymerase chain reaction and Western blot.
  
  
  RESULTS
  Ac treatment produced an increment in IL-8 induction and secretion that was prevented by IL-4 pretreatment, while IL-10 pretreatment failed to decrease Ac-induced IL-8 production. Consistent with these findings Ac increased NF-kappa B and AP-1 activation that were prevented by IL-4 but not by IL-10, findings accompanied by greater I kappa B-alpha levels in IL-4 but not IL-10 pretreated cells. In contrast to the pro-inflammatory role of IL-10 in HepG2, IL-10 did not show any change in the activation of NF-kappa B by Ac in WRL-68 cells, a human fetal hepatic cell line. Moreover, IL-10 did not induce the degradation of I kappa B-alpha in cellular extract from rat primary cultured cells.
  
  
  CONCLUSIONS
  While the present findings demonstrate the anti-inflammatory role of IL-4 in preventing the expression of IL-8 by Ac, the regulation of chemokines by anti-inflammatory cytokines is complex and depends on the cellular lineage.
authors.affiliation: Experimental Biology PhD Program, Universidad Autonoma Metropolitana-Iztapalapa, Mexico D.F. 09340, Mexico.
authors.forename: Luis Enrique
authors.initials: LE
authors.lastname: Gómez-Quiroz
authors.forename: Raquel
authors.initials: R
authors.lastname: Paris
authors.forename: José María
authors.initials: JM
authors.lastname: Lluis
authors.forename: Leticia
authors.initials: L
authors.lastname: Bucio
authors.forename: Verónica
authors.initials: V
authors.lastname: Souza
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Hernández
authors.forename: Mario
authors.initials: M
authors.lastname: Gutiérrez
authors.forename: Mariana
authors.initials: M
authors.lastname: Santiago
authors.forename: Carmen
authors.initials: C
authors.lastname: García-Ruiz
authors.forename: José C
authors.initials: JC
authors.lastname: Fernández-Checa
authors.forename: David
authors.initials: D
authors.lastname: Kershenobich
authors.forename: Ma Concepción
authors.initials: MC
authors.lastname: Gutiérrez-Ruiz
mesh_terms: D000079:Acetaldehyde / Q000494:pharmacology*; D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor / Q000187:drug effects / Q000473:pathology; D004338:Drug Combinations; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D020672:I-kappa B Proteins / Q000378:metabolism; D016753:Interleukin-10 / Q000494:pharmacology*; D015847:Interleukin-4 / Q000494:pharmacology*; D016209:Interleukin-8 / Q000235:genetics / Q000378:metabolism*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018808:Transcription Factor AP-1 / Q000378:metabolism
chemical_list: D004338:Drug Combinations; C083487:I kappa B beta protein; D020672:I-kappa B Proteins; D016209:Interleukin-8; D016328:NF-kappa B; C000606204:NFKBIA protein, human; C000606206:Nfkbia protein, rat; D012333:RNA, Messenger; D018808:Transcription Factor AP-1; D016753:Interleukin-10; D000072000:NF-KappaB Inhibitor alpha; D015847:Interleukin-4; D000079:Acetaldehyde